Exenatide Plus Dapagliflozin Combination: Better Metabolic Outcomes Than Either Alone
Combining exenatide (GLP-1 agonist) with dapagliflozin (SGLT2 inhibitor) provided superior metabolic management compared to either drug alone in type 2 diabetes patients.
Quick Facts
What This Study Found
Exenatide + dapagliflozin combination achieved superior HbA1c reduction, weight loss, and metabolic outcomes versus either drug alone through complementary mechanisms.
Key Numbers
Mean differences with 95% confidence intervals were calculated. Four databases were searched for relevant RCTs.
How They Did This
Clinical study comparing exenatide + dapagliflozin combination vs monotherapy. Assessed HbA1c, body weight, metabolic parameters.
Why This Research Matters
Combining drugs with different mechanisms should produce additive benefits — and this study confirms it. GLP-1 + SGLT2 combinations could become standard for patients needing aggressive metabolic management.
The Bigger Picture
GLP-1 + SGLT2 combinations address diabetes from two angles simultaneously: GLP-1 improves insulin function and reduces appetite, while SGLT2 eliminates excess glucose through the kidneys. This dual approach also provides cardiovascular and kidney protection from both drug classes.
What This Study Doesn't Tell Us
Study specifics vary. Cost of dual therapy is higher. Some patients may experience more side effects with combination.
Questions This Raises
- ?Is GLP-1 + SGLT2 combination better than GLP-1 + metformin for initial therapy?
- ?Do cardiovascular and kidney benefits add synergistically with combination?
- ?Should all T2D patients receive combination GLP-1 + SGLT2 therapy?
Trust & Context
- Key Stat:
- Combination wins GLP-1 agonist + SGLT2 inhibitor combination provides superior metabolic outcomes through complementary mechanisms
- Evidence Grade:
- Moderate evidence: clinical comparison showing combination superiority over monotherapy.
- Study Age:
- Published in 2025. Supports the trend toward combination metabolic therapy.
- Original Title:
- Efficacy of the Combination of Exenatide and Dapagliflozin in the Management of Diabetes and Weight Control: A Network Meta-Analysis.
- Published In:
- Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2025)
- Authors:
- Abuali, Ahmed, Abdelhamid, Abdelrahman, Elsekaily, Ahmed Elsayed, Seoudy, Mohamed, Elnaghy, Mohamed, Ragab, Youssef, Elkholy, Mohammed, Sharara, Muhannad, Mahrous, Mostafa, Alnasser, Yusra, Ragab, Khaled Mohamed, Abdelhadi, Naser
- Database ID:
- RPEP-09754
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Why combine two diabetes drugs?
Exenatide and dapagliflozin work through completely different mechanisms — one enhances insulin and reduces appetite, the other removes excess glucose through the kidneys. Together they achieve better blood sugar control and more weight loss than either alone.
Is combination therapy worth the extra cost?
For many patients, yes. Better metabolic control prevents expensive complications (heart disease, kidney failure, amputations). The combination also provides dual cardiovascular and kidney protection. Discuss cost-benefit with your healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09754APA
Abuali, Ahmed; Abdelhamid, Abdelrahman; Elsekaily, Ahmed Elsayed; Seoudy, Mohamed; Elnaghy, Mohamed; Ragab, Youssef; Elkholy, Mohammed; Sharara, Muhannad; Mahrous, Mostafa; Alnasser, Yusra; Ragab, Khaled Mohamed; Abdelhadi, Naser. (2025). Efficacy of the Combination of Exenatide and Dapagliflozin in the Management of Diabetes and Weight Control: A Network Meta-Analysis.. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. https://doi.org/10.1055/a-2737-6110
MLA
Abuali, Ahmed, et al. "Efficacy of the Combination of Exenatide and Dapagliflozin in the Management of Diabetes and Weight Control: A Network Meta-Analysis.." Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2025. https://doi.org/10.1055/a-2737-6110
RethinkPeptides
RethinkPeptides Research Database. "Efficacy of the Combination of Exenatide and Dapagliflozin i..." RPEP-09754. Retrieved from https://rethinkpeptides.com/research/abuali-2025-efficacy-of-the-combination
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.